Hypopharyngeal cancer is a type of head and neck cancer that originates in the hypopharynx, the part of the bottom of the throat that meets the esophagus. Alfa Cytology is a world leader in the head and neck cancer field. With our extensive experience and advanced platform, we can provide the best solutions for hypopharyngeal cancer.
Introduction to Hypopharyngeal Cancer
Hypopharyngeal cancer is a relatively rare cancer, but it is aggressive and challenging to treat and is usually not diagnosed until it has spread to surrounding tissues. Hypopharyngeal cancer is associated with multiple risk factors, which can lead to genetic mutations in normal cells, leading to uncontrolled proliferation of cells in the hypopharyngeal site and the malignant development of cancerous tumors.
Therapy for Hypopharyngeal Cancer
Traditional therapy options for hypopharyngeal cancer often include surgery, radiation therapy, and chemotherapy. However, with the latest research progress of cancer mechanisms, the new therapy development for hypopharyngeal cancer has become an upsurge.
Immunotherapy
With the development of new therapies, immunotherapy has become a promising therapy that can prevent or treat cancer by activating the body's immune system to recognize and attack cancer cells. Among them, immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown good efficacy against some advanced hypopharyngeal cancers.
Target Therapy
Targeted therapies aim to disrupt specific molecular pathways to enhance tumor immune response. Recent studies have identified some potential cancer epitopes or targets in hypopharyngeal cancer that may be useful for targeted therapy. Drugs targeting specific molecular pathways, such as EGFR inhibitors like cetuximab, are being studied for their role in treating hypopharyngeal cancer.
Targets of Hypopharyngeal Cancer Therapy Development
With the continuous development of biological technology, more potential targets will gradually be identified.
- Epidermal Growth Factor Receptor
- Vascular Endothelial Growth Factor
- Checkpoint Kinase 1
- Programmed Cell Death 1
- Human Epidermal Growth Factor Receptor 2
Fig.1 53 driver genes associated with hypopharyngeal cancer. (Yao, J., et al., 2023)
Our Services
Research on hypopharyngeal cancer focuses on improving early detection methods, perfecting therapy strategies, and exploring innovative therapies such as targeted drugs and immunotherapies. Therefore, Alfa Cytology is working on providing one-stop solutions for hypopharyngeal cancer, including but not limited to the following.
Models of Hypopharyngeal Cancer
The hypopharyngeal cancer model is a key tool in uncovering the complexities of this cancer. Alfa Cytology offers a range of models tailored to simulate the development and progression of hypopharyngeal cancer.
Alfa Cytology also offers a range of animal model options specifically designed for hypopharyngeal cancer research, the species include mice, rats, zebrafish, chicks, dogs, non-human primates, and others.
Alfa Cytology is committed to the research and study of cancer, from therapeutic antibody development services, cancer vaccine development services, to cancer modeling services, providing one-stop solutions. Our cancer experts have many years of experience in the development of the latest therapies for hypopharyngeal cancer. If you are interested in our service, please contact us for more details.
Reference
- Yao, J., et al.; (2023). Application value of whole exome sequencing in screening and identifying novel mutations of hypopharyngeal cancer. Scientific Reports, 13(1), 107.
For research use only.
Related Services
